×
About 4,399 results

ALLMedicine™ Biosimilars Center

Research & Reviews  1,707 results

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimum...
https://doi.org/10.1001/jamadermatol.2021.0221
JAMA Dermatology; Loft N, Egeberg A et. al.

Apr 7th, 2021 - The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars. To assess the outcomes foll...

Biosimilars in Dermatology.
https://doi.org/10.1001/jamadermatol.2021.0219
JAMA Dermatology; Lebwohl M

Apr 7th, 2021 - Biosimilars in Dermatology.|2021|Lebwohl M,|

Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Con...
https://doi.org/10.1007/s43441-021-00280-1 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1863::AID-SIM989>3.0.CO;2-M
Therapeutic Innovation & Regulatory Science; Pan Z, Huang W et. al.

Apr 2nd, 2021 - The development of biosimilars has substantially increased in recent years. A biosimilar is a biological product which is highly similar to a licensed biological product (reference product), with no clinically meaningful differences between the pr...

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: ...
https://doi.org/10.1080/14737167.2021.1910026
Expert Review of Pharmacoeconomics & Outcomes Research; Šprem Goldštajn M, Mikuš M et. al.

Mar 31st, 2021 - Introduction: To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order ...

A Review of Formulations of Commercially Available Antibodies.
https://doi.org/10.1016/j.xphs.2021.03.017
Journal of Pharmaceutical Sciences; Strickley RG, Lambert WJ

Mar 31st, 2021 - This review identified 126 commercially available antibodies approved globally between 1986 and February 2021 including 10 antibody drug conjugates, 16 biosimilars, and 3 antibody fragments. Prior to 2014 there were ≤ 5 approved each year, but aft...

see more →

Guidelines  31 results

Blood Cancer Experts Discuss Latest Treatment Innovations at NCCN 2019 Annual Congress: Hematologic Malignancies™
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1678

Sep 9th, 2019 - World-renowned experts on blood cancers are meeting in San Francisco on September 27-28, to help clinicians stay up-to-date on new, practice-changing strategies to manage patients with hematologic malignancies, at the NCCN 2019 Annual Congress: He...

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL...

Biosimilars: Not Simply Generics
https://www.uspharmacist.com/article/biosimilars-not-simply-generics

Jun 17th, 2019 - With the entry of biosimilars into the U.S. market, it is important for pharmacists to understand these products and how they differ from generic medications.

PANLAR consensus statement on biosimilars
https://link.springer.com/article/10.1007/s10067-019-04496-3

Mar 26th, 2019 - Biologics have improved the treatment of rheumatic diseases, resulting in better outcomes. However, their high cost limits access for many patients in both North America and Latin America. Following patent expiration for biologicals, the availabil...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  2,135 results

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimum...
https://doi.org/10.1001/jamadermatol.2021.0221
JAMA Dermatology; Loft N, Egeberg A et. al.

Apr 7th, 2021 - The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars. To assess the outcomes foll...

Biosimilars in Dermatology.
https://doi.org/10.1001/jamadermatol.2021.0219
JAMA Dermatology; Lebwohl M

Apr 7th, 2021 - Biosimilars in Dermatology.|2021|Lebwohl M,|

Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Con...
https://doi.org/10.1007/s43441-021-00280-1 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1863::AID-SIM989>3.0.CO;2-M
Therapeutic Innovation & Regulatory Science; Pan Z, Huang W et. al.

Apr 2nd, 2021 - The development of biosimilars has substantially increased in recent years. A biosimilar is a biological product which is highly similar to a licensed biological product (reference product), with no clinically meaningful differences between the pr...

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: ...
https://doi.org/10.1080/14737167.2021.1910026
Expert Review of Pharmacoeconomics & Outcomes Research; Šprem Goldštajn M, Mikuš M et. al.

Mar 31st, 2021 - Introduction: To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order ...

A Review of Formulations of Commercially Available Antibodies.
https://doi.org/10.1016/j.xphs.2021.03.017
Journal of Pharmaceutical Sciences; Strickley RG, Lambert WJ

Mar 31st, 2021 - This review identified 126 commercially available antibodies approved globally between 1986 and February 2021 including 10 antibody drug conjugates, 16 biosimilars, and 3 antibody fragments. Prior to 2014 there were ≤ 5 approved each year, but aft...

see more →

News  525 results

'Major Advancement' in Preventing Neutropenia, Says Trialist
https://www.medscape.com/viewarticle/944603

Jan 24th, 2021 - In the United States, for the past two decades, pegfilgrastim (Neulasta) and its biosimilars have been the widely used standard of care for the prevention of chemotherapy-induced neutropenia (CIN). Now, the champions of a new agent, plinabulin (Be...

Thiopurine Monotherapy Effective in Ulcerative Colitis, But Less So in Crohn’s Disease
https://www.staging.medscape.com/viewarticle/939337

Oct 18th, 2020 - Takeaway Thiopurine monotherapy is an effective long-term treatment for ulcerative colitis (UC), but significantly less effective in Crohn’s disease (CD), particularly where there is perianal involvement. Why this matters Given recent substantial ...

Thiopurine Monotherapy Effective in Ulcerative Colitis, But Less So in Crohn’s Disease
https://www.medscape.com/viewarticle/939337

Oct 18th, 2020 - Takeaway Thiopurine monotherapy is an effective long-term treatment for ulcerative colitis (UC), but significantly less effective in Crohn’s disease (CD), particularly where there is perianal involvement. Why this matters Given recent substantial ...

Pharmacists Not Required to Substitute Generics for Brand-Name Drugs in Most US States
https://www.medscape.com/viewarticle/936613

Aug 31st, 2020 - (Reuters Health) - Only 19 U.S. states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available, with the 31 remaining states allowing but not requiring these substitutions, a new study finds. Re...

English CCGs 'Miss Out on Biosimilar Insulin Glargine Savings'
https://www.medscape.com/viewarticle/932303

Jun 14th, 2020 - A study has found that primary care providers in England only realised a fraction of potential savings from adopting insulin glargine biosimilars over a period of just over 3 years. An analysis in the journal Diabetes Care found that insulin glarg...

see more →